Actuate Therapeutics, Inc., was incorporated in Delaware on January 16, 2015 as Apotheca Therapeutics, Inc., and changed its name to Actuate Therapeutics, Inc., on October 1, 2015. The company is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers by inhibiting glycogen synthase kinase 3 (GSK-3). They are developing elraglusib (formerly 9-ING-41), a small molecule designed to enter cancer cells and block the function of the GSK-3β enzyme, a major regulator of complex biological signaling cascades, including oncogene-mediated signaling cascades that lead to tumor cell survival, growth, migration and invasion. 

ACTU

ACTU Profile